This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Persistence of Oral Tolerance to Peanut (LEAP-On)

This study has been completed.
Sponsor:
Collaborator:
Immune Tolerance Network (ITN)
Information provided by (Responsible Party):
National Institute of Allergy and Infectious Diseases (NIAID)
ClinicalTrials.gov Identifier:
NCT01366846
First received: June 2, 2011
Last updated: January 30, 2017
Last verified: January 2017
Results First Received: November 8, 2016  
Study Type: Interventional
Study Design: Allocation: Non-Randomized;   Intervention Model: Parallel Assignment;   Masking: No masking;   Primary Purpose: Treatment
Conditions: Eczema
Egg Allergy
Food Allergy
Hypersensitivity
Intervention: Other: Avoidance of peanut

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
From among those who completed the LEAP study (protocol ID ITN032AD, ClinicalTrials.gov ID NCT00329784), 556 subjects were recruited between 26 May 2011 and 6 June 2014 at Evelina Children’s Hospital in London, UK.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
In the LEAP trial, participants were stratified into strata based on a peanut allergen skin prick test (SPT). Participants were either SPT negative (0mm wheal) or SPT positive (1-4 mm wheal). Participants were then randomized into treatment groups within each stratum. This configuration was preserved in LEAP-On (this trial)

Reporting Groups
  Description
Negative Stratum – Continued Peanut Avoidance Group Participants who had a negative response to a peanut allergen skin prick test (no measurable wheal) and were then randomized into the peanut avoidance group for the duration of LEAP (protocol ID ITN032AD, ClinicalTrials.gov ID NCT00329784). As with participants of all treatment groups, these participants avoided peanut protein during the following LEAP-On study (this trial)
Negative Stratum – Peanut Avoidance After Consumption Group Participants who had a negative response to a peanut allergen skin prick test (no measurable wheal) and were then randomized into the peanut consumption group for the duration of LEAP (protocol ID ITN032AD, ClinicalTrials.gov ID NCT00329784). As with participants of all treatment groups, these participants avoided peanut protein during the following LEAP-On study (this trial).
Positive Stratum – Continued Peanut Avoidance Group Participants who had a positive response to a peanut allergen skin prick test (a wheal measuring between 1 and 4 mm) and were then randomized into the peanut avoidance group for the duration of LEAP (protocol ID ITN032AD, ClinicalTrials.gov ID NCT00329784). As with participants of all treatment groups, these participants avoided peanut protein during the following LEAP-On study (this trial).
Positive Stratum – Peanut Avoidance After Peanut Consumption G Participants who had a positive response to a peanut allergen skin prick test (a wheal measuring between 1 and 4 mm) and were then randomized into the peanut consumption group for the duration of LEAP (protocol ID ITN032AD, ClinicalTrials.gov ID NCT00329784). As with participants of all treatment groups, these participants avoided peanut protein during the following LEAP-On study (this trial).

Participant Flow:   Overall Study
    Negative Stratum – Continued Peanut Avoidance Group   Negative Stratum – Peanut Avoidance After Consumption Group   Positive Stratum – Continued Peanut Avoidance Group   Positive Stratum – Peanut Avoidance After Peanut Consumption G
STARTED   235   228   47   46 
COMPLETED   232   224   46   45 
NOT COMPLETED   3   4   1   1 
Withdrawal by Subject                2                0                0                0 
Communication Difficulties                1                4                0                1 
Scheduling Conflicts                0                0                1                0 



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
Intent-to-treat

Reporting Groups
  Description
Negative Stratum - Peanut Avoidance Group Participants who had a negative response to a skin prick test for peanut allergen (no measurable wheal) and were then randomized to the peanut avoidance group. Participants were instructed to avoid exposure to peanut protein during study participation.
Negative Stratum - Peanut Consumption Group Participants who had a negative response to a skin prick test for peanut allergen (no measurable wheal) and were then randomized to the peanut consumption group. Participants were fed at least 2 g of peanut protein 3 times per week (a total of 6g). The preferred peanut source was Bamba (a peanut snack), although peanut butter was an acceptable substitute. After age 3, participants were allowed to eat whole peanuts.
Positive Stratum - Peanut Avoidance Group Participants who had a positive response to a skin prick test for peanut allergen (a wheal measuring between 1 and 4 mm) and were then randomized to the peanut avoidance group. Participants were instructed to avoid exposure to peanut protein during study participation.
Positive Stratum - Peanut Consumption Group Participants who had a positive response to a skin prick test for peanut allergen (a wheal measuring between 1 and 4 mm) and were then randomized to the peanut consumption group. Participants were fed at least 2 g of peanut protein 3 times per week (a total of 6g). The preferred peanut source was Bamba (a peanut snack), although peanut butter was an acceptable substitute. After age 3, participants were allowed to eat whole peanuts.
Total Total of all reporting groups

Baseline Measures
   Negative Stratum - Peanut Avoidance Group   Negative Stratum - Peanut Consumption Group   Positive Stratum - Peanut Avoidance Group   Positive Stratum - Peanut Consumption Group   Total 
Overall Participants Analyzed 
[Units: Participants]
 235   228   47   46   556 
Age, Customized 
[Units: Months]
Mean (Standard Deviation)
         
Age in Months   61.0  (3.44)   61.7  (4.19)   60.6  (3.76)   61.4  (4.98)   61.3  (3.93) 
Sex: Female, Male 
[Units: Participants]
Count of Participants
         
Female      85  36.2%      102  44.7%      14  29.8%      18  39.1%      219  39.4% 
Male      150  63.8%      126  55.3%      33  70.2%      28  60.9%      337  60.6% 
Region of Enrollment 
[Units: Participants]
         
United Kingdom   235   228   47   46   556 


  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Number of Participants With Peanut Allergy (PA) at 72 Months of Age – by Skin Prick Test Stratum   [ Time Frame: 72 months ]

2.  Primary:   Number of Participants With Peanut Allergy (PA) at 72 Months of Age – by Treatment Group   [ Time Frame: 72 months ]

3.  Primary:   Number of Participants With Peanut Allergy (PA) at 72 Months of Age – by Skin Prick Test Stratum in the Per Protocol Population   [ Time Frame: 72 months ]

4.  Primary:   Number of Participants With Peanut Allergy (PA) at 72 Months of Age – by Treatment Group in the Per Protocol Population   [ Time Frame: 72 months ]

5.  Secondary:   Number of Participants With Peanut Allergy (PA) at 60- and 72-month Visits Within the Peanut Avoidance After Peanut Consumption Group   [ Time Frame: 60 months and 72 months ]

6.  Secondary:   Number of Peanut Avoidance After Peanut Consumption Group Participants With Peanut Allergy (PA) at 60- and 72-month Visits Within in the Per Protocol Population   [ Time Frame: 60 months and 72 months ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.


Results Point of Contact:  
Name/Title: Director, Clinical Research Operations Program
Organization: DAIT/NIAID
phone: 301-594-7669
e-mail: DAITClinicalTrialsGov@niaid.nih.gov


Publications of Results:
Other Publications:

Responsible Party: National Institute of Allergy and Infectious Diseases (NIAID)
ClinicalTrials.gov Identifier: NCT01366846     History of Changes
Other Study ID Numbers: DAIT ITN049AD
Study First Received: June 2, 2011
Results First Received: November 8, 2016
Last Updated: January 30, 2017